Presentation of the new ChemBioBank laboratory Blog Post

Today Thursday, July 23rd, the Barcelona Science Park held the presentation ceremony of the new ChemBioBank laboratory, a Spanish initiative that aims to create an organized library of chemical compounds, mainly of academic origin, and their characterization via virtual and experimental screening methods. The general director of the Barcelona Science Park, Fernando Albericio, and representatives of the three institutions that promote the ChemBioBank – Jordi Quintana, manager of the Drug Discovery Platform (PDD) of the Barcelona Science Park (PCB) and coordinator of the project; Mabel Loza, coordinator of the Screening Platform, University of Santiago de Compostela (USC), and Ferran Sanz, director of the Biomedical Informatics programme of the Municipal Institute of Medical Research of Barcelona (IMIM)-, have participated in the event.

The Drug Discovery Platform of the Barcelona Science Park presents the new ChemBioBank laboratory Blog Post

The presentation ceremony of the new laboratory has taken place today in the Cluster Building of the Barcelona Science Park. ChemBioBank is a Spanish initiative– coordinated by the Drug Discovery Platform located at the PCB- which aims to create an organized library of chemical compounds, mainly of academic origin, and to be characterized by virtual and experimental screening methods, in order to generate an annotated chemical-biological database.

New public-private open innovation project for the repositioning of 20 drugs Blog Post

A public-private open innovation project to discover new drugs based on repurposing (repositioning)- the result of a collaboration agreement between the Drug Discovery Platform (DDP) at the Barcelona Science Park (PCB) and the companies SOM Biotech and Metasbio, both located at the PCB, has obtained a grant of 441,884 Euros from the Genome Spain Foundation through the Innocash credit line. Initially, the three partners have selected therapeutic areas characterized by a high medical need and market potential, particularly central nervous system diseases, orphan diseases, and oncology

The success of the 4th edition of the SSM consolidates the initiative as a training program relating to the biopharmaceutical sector Blog Post

The fourth edition of the Summer School of Medicine (SSM4), held from 2 to 13 July in the cities of Montreal and Quebec City (Canada) concluded last Friday. As the previous edition, the SSM3, which took place at the Barcelona Science Park (PCB) in July 2011 – more than 40 international experts from the pharmaceutical and biotech industries and academic research informed all participants of all phases of production and development of medicines, from inception to arrival to the market, including important issues such as business development, financing (venture capital), Public-Private Partnership (PPP), market access and open innovation. The panel was formed by renowned professionals such as Jordi Quintana, Technical Director of Business Development at the Barcelona Science Park and head of the Drug Discovery Platform, and Ivo Gut, director of the National Center for Genome Analysis (CNAG), based at the PCB.

Humanfarma a project of public-private partnership of translational research for drug discovery Blog Post

The Barcelona Science Park (PCB) is a member of the consortium Humanfarma, whose goal is to develop new active compounds for drug discovery through translational research directly in patient samples. The project, which has a budget of 4.1 M € and will be partially financed by the Ministry of Economy and Competitiveness under the subprogramme Innpacto – also involves the participation of the University of Santiago de Compostela (USC) and four biotech companies: GalChimia, Oryzon Genomics, Vivia Allosterics and Vivia Biotech, coordinator of the project.

PCB takes part at the 14th European Congress on Biotechnology Blog Post

Framed within the European Congress on Biotechnology being held at the Palau de Congressos de Catalunya (Barcelona) until the 16th of September, ACC1Ó and Biocat have organised today at 18.30h a session entitled “European Business and Technology Center (EBTC): EU-India Business Gateway Seminar”. The aim of this session is to analyse the business opportunities that India brings to European companies. Different experts from several institutions will be participating at this round table, including Fernando Albericio, director general of the Barcelona Science Park (PCB). PCB joined the agreement signed at BioAsia 2009 between Biocat and Genome Valley, the main biocluster of India, in order to jointly promote acitivities in the biotechnology sector. Other invited guests include Shakti Meggapan, of the Asian Federation of Biotechnological Associations; Isidre Sala (COPCA), on behalf of the Eurochambers consortium promoted by the EBTC – an EU-funded service aimed at increasing European participation in the Indian biotechnology market–, and Jordi Bacardit, from SVS, a Catalan company in Mumbai.

Drug Discovery Platform to offer more services Blog Post

The Drug Discovery Platform has recently moved to new premises on the ground floor of the Modular Building of the Barcelona Science Park (PCB), from where it will continue its consultancy work and will also offer computational research and technology services for analysing compound databases with the aim of facilitating and speeding up the design process for new drugs.

Barcelona Hosts European Chemical Biology Symposium in July Blog Post

On 10 and 11 July, Barcelona is set to host the European Chemical Biology Symposium (ECBS 2008), organised jointly by the Barcelona Science Park and the Municipal Institute for Medical Research (IMIM-Hospital del Mar). The purpose of the gathering is to bring together researchers in diverse areas connected to chemical biology to give presentations and take part in debates on lines of research currently underway. Participants will consider the field’s outlook for the future as well as joint initiatives under development in this emerging area.